Healthcare AI startup RISA Labs has raised $11.1 million (over ₹100 crore) in a Series A funding round co-led by US-based VC powerhouses Cencora Ventures and Optum Ventures.
Founded in June 2024 by Kshitij Jaggi and Kumar Shivang, the Palo Alto-based startup is tackling one of medicine's most complex administrative challenges: Oncology workflows.
FounderStory Intelligence
Meet BOSS: The AI Agent for Oncologists
RISA's flagship product is BOSS, an AI-powered console designed to simplify the intricate workflows of cancer care. Oncology is notoriously complex due to multi-drug regimens, strict payer rules, and disease-specific requirements.
BOSS breaks these massive administrative burdens into smaller tasks handled by AI agents, allowing clinicians to focus on patient care rather than paperwork.
Strategic Backing
The investment round saw participation from specialized funds like Oncology Ventures and z21 Ventures, as well as John Simon (General Catalyst co-founder) via VentureForGood. The fresh capital will be used to scale distribution across cancer clinics, health systems, and specialty pharmacies in the US.
"The AI OS is purpose-built for the realities of cancer care, handling complex payer rules, multi-drug regimens, and disease-specific requirements."
FounderStory Takeaway
Healthcare AI is moving from "General" to "Vertical." RISA Labs exemplifies this shift by building a deep, purpose-built OS for a single high-value vertical: Oncology. With backers like Cencora and Optum (who deeply understand the US healthcare payer/provider landscape), RISA is positioned to solve the "administrative toxicity" in cancer care.